MedTrace Logo

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

NCT01658384 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2019-03-06

No results posted yet for this study

Summary

This study is designed to evaluate the effect of Tysabri on cognition in multiple sclerosis (MS) patients. During a period of 24 months, the study will assess the evolution of cognitive function in Tysabri treated MS patients using the Symbol Digit Modalities Test (SDMT) and the CogState battery of tests.

Conditions

Sponsors & Collaborators

  • CogState Ltd.

    collaborator INDUSTRY

  • Clinique Neuro-Outaouais

    lead OTHER

Principal Investigators

  • François H Jacques, MD · Clinique Neuro-Outaouais

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2015-02-28
Completion
2015-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01658384 on ClinicalTrials.gov